Human studies have demonstrated that higher circulating LCN2 levels are associated with obesity, insulin resistance, and dyslipidemia in T2D patients, thereby proposing LCN2 as a serum marker for metabolic disorders [106,107]. The gene discussed is LCN2; the disease is obesity disorder.